Quick Answer
Krystal Biotech, Inc. reported Diluted EPS of $6.84 per share for fiscal year 2025.
Krystal Biotech, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $6.84 | +128.0% |
| 2024 | $3.00 | +669.2% |
| 2023 | $0.39 | +107.1% |
| 2022 | -$5.49 | -75.4% |
| 2021 | -$3.13 | -83.0% |
| 2020 | -$1.71 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.66 | +192.3% | +106.2% |
| June 30, 2025 | $1.29 | +143.4% | +7.5% |
| March 31, 2025 | $1.20 | +3900.0% | +31.9% |
| September 30, 2024 | $0.91 | -67.4% | +71.7% |
| June 30, 2024 | $0.53 | +142.4% | +1666.7% |
| March 31, 2024 | $0.03 | +101.7% | -98.9% |
| September 30, 2023 | $2.79 | +338.5% | +323.2% |
| June 30, 2023 | -$1.25 | -13.6% | +29.0% |
- Krystal Biotech, Inc. showed an increase of +128.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Krystal Biotech, Inc.’s diluted eps has grown by 500.0% (from $1.71 per share (loss) to $6.84 per share).
- The most recent figure is from Krystal Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: